Celiac disease diagnosis in clinical practice: ESPGHAN quality of care survey from 129 pediatric hospitals across 28 countries
Journal of Pediatric Gastroenterology and Nutrition · 2025-09 · 81 (3) · 606-617
DOI: 10.1002/jpn3.70143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 07.07.2025. Verfasst von Anna Litwin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology, Dr. von Hauner Children's Hospital, LMU University Hospital Munich, …. Hauptthemen laut MEDLINE: Celiac Disease, Practice Patterns, Physicians', Quality of Health Care. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ESPGHAN, Ludwig Maximilians Universität Munich.
Abstract (Originalsprache)
Objectives
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines recommend first‐line serology for suspected celiac disease (CeD), measuring only transglutaminase antibodies (TGA‐immunoglobulin A [IgA]) plus total IgA. If TGA‐IgA is ≥10 times the normal value, pediatric gastroenterologists (pedGI) may diagnose CeD without biopsies if autoantibodies against endomysial antibodies (EMA‐IgA) are positive in a 2nd blood sample. This Quality‐of‐Care (QoC) project benchmarked diagnostic workup in clinical practice using ESPGHAN CeD guidelines as reference.
Methods
A pseudonymized survey on CeD practices was sent to 141 hospitals within the ESPGHAN QoC‐network in 28 countries.
Results
Questionnaires were completed by 129/141 (91.5%) hospitals, with 121 (94%) having pedGI staff. As reasons conflicting with good QoC for CeD in their setting, responders assumed knowledge deficits among the public (57%), primary care providers (64%), non‐GI physicians (16%), and pedGIs (0%). For initial testing, 66% of physicians ordered only total IgA and TGA‐IgA, 7% did not use this combination, and 29% ordered additional serology (TGA‐IgG, EMA, antibodies against deaminated gliadin peptide, or native gliadin). Regarding conflicting results for TGA‐IgA and histopathology in IgA‐sufficient children, 61% incorrectly classified negative TGA‐IgA with Marsh 2 and 57% with Marsh 3 lesions as “potential CeD,” while 49% excluded CeD in the case of villous atrophy and negative TGA‐IgA. Routine practice did not align with the ESPGHAN recommendations regarding performance of duodenal biopsies (27%), EMA‐testing (34%), and diagnosis of CeD in IgA‐deficient children (32%).
Conclusions
We identified areas for improving QoC regarding both effectiveness and efficacy, in pediatric patients with suspected CeD, and consequently developed easy‐to‐use tools to improve guideline implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology, Dr. von Hauner Children's Hospital, LMU University Hospital Munich, LMU Munich, Munich, Germany.
- Stiftung Kindergesundheit, c/o Dr. von Hauner Children's Hospital, LMU University Hospital Munich, LMU Munich, Munich, Germany.
- Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
- Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The Netherlands.
- Department of Hygiene and Epidemiology, Faculty of Public Health, Prof. Paraskev Stoyanov Medical University, Varna, Bulgaria.
- Human Nutrition, School of Medicine, University of Glasgow, Glasgow, United Kingdom of Great Britain and Northern Ireland.
ORCID-Profile: Sibylle Koletzko
Förderung
- ESPGHAN
- Ludwig Maximilians Universität Munich
Zitieren
APA
Litwin, A., Le Thi, T. G., El-Lababidi, N., Kindermann, A., Pancheva, R., Gerasimidis, K., Goncalves, C. C., Escobar, P. C., Niseteo, T., Ikrath, K., Koletzko, S., & Quality‐of‐Care Network (2025). Celiac disease diagnosis in clinical practice: ESPGHAN quality of care survey from 129 pediatric hospitals across 28 countries. Journal of Pediatric Gastroenterology and Nutrition, 81(3), 606-617. https://doi.org/10.1002/jpn3.70143
Vancouver
Litwin A, Le Thi TG, El-Lababidi N, Kindermann A, Pancheva R, Gerasimidis K, et al. Celiac disease diagnosis in clinical practice: ESPGHAN quality of care survey from 129 pediatric hospitals across 28 countries. Journal of Pediatric Gastroenterology and Nutrition. 2025;81(3):606-617. doi:10.1002/jpn3.70143
BibTeX
@article{Litwin2025,
author = {Litwin, Anna and Le Thi, Thu Giang and El-Lababidi, Nabil and Kindermann, Angelika and Pancheva, Rouzha and Gerasimidis, Konstantinos and Goncalves, Cristina Campos and Escobar, Paula Crespo and Niseteo, Tena and Ikrath, Katharina and Koletzko, Sibylle and Quality‐of‐Care Network, Quality‐of‐Care Network},
title = {Celiac disease diagnosis in clinical practice: ESPGHAN quality of care survey from 129 pediatric hospitals across 28 countries},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
volume = {81},
number = {3},
pages = {606--617},
doi = {10.1002/jpn3.70143}
}
EUVIMED